Tounjian Advisory Partners’s Pfizer PFE Stock Holding History

Tounjian Advisory Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.7K	Sell	776 -74,672	-99%	-$1.95M	0.01%	308
2026 Q1	$2.12M	Buy	75,448 +5,218	+7%	+$139K	0.77%	42
2025 Q4	$1.75M	Sell	70,230 -752	-1%	-$19K	0.59%	55
2025 Q3	$1.81M	Buy	70,982 +21,126	+42%	+$521K	0.61%	50
2025 Q2	$1.26M	Sell	49,856 -696	-1%	-$16.2K	0.24%	107
2025 Q1	$1.28M	Buy	+50,552	New	+$1.32M	0.24%	107

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Tounjian Advisory Partners's PFE Position: Q2 2026 in Review

Tounjian Advisory Partners reduced its Pfizer (PFE) stake by 99% in Q2 2026, selling an estimated $1.95M and leaving 776 shares worth $18.7K. The position accounts for 0.01% of the portfolio, ranked #308.

Tounjian Advisory Partners first reported a position in PFE in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.12M in Q1 2026. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Tounjian Advisory Partners held 776 shares of Pfizer worth $18.7K as of Q2 2026.
Tounjian Advisory Partners sold 74,672 Pfizer shares in Q2 2026, an estimated $1.95M.
Pfizer made up 0.01% of Tounjian Advisory Partners's portfolio in Q2 2026, its #308 holding.
Tounjian Advisory Partners first reported a position in Pfizer in Q1 2025 and has held it in 6 quarters since.
Tounjian Advisory Partners's Pfizer position peaked at $2.12M in Q1 2026.
2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Tounjian Advisory Partners's 13F filing for Q2 2026, filed 7 Aug 2026.